New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination

Effectiveness of Covaxin against the Omicron variant is currently being studied

Six benefits of Cloud Computing in the pharma industry

Pfizer’s Covid-19 drug 90 % effective

The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation

Moderna to set up mRNA vaccine manufacturing facility in Australia

Up to 100 million mRNA vaccine doses could be produced in Australia each year

ICMR Dibrugarh designs kit to detect Omicron variant in two hours

GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model

Moderna announces positive interim Phase 1 data for mRNA flu vaccine

Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed

Alembic acquires stake in RIGlmmune

The company is focused on the development of novel treatments for RNA viruses

Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials

Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants

Aerogen partners with CanSinoBIO for aerosolised Covid-19 vaccine

The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.

USFDA authorises Astra’s antibody cocktail to prevent Covid

Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19